Literature DB >> 30427735

Racial Differences in Escitalopram/Citalopram-Related Weight Gain in Children and Adolescents: A Natural Language Processing-Based Electronic Medical Record Study.

Laura B Ramsey1, Stacey L Aldrich2, Ethan Poweleit1, Cynthia A Prows3, Lisa J Martin4,5, Jeffrey R Strawn6,7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30427735      PMCID： PMC6442232          DOI： 10.1089/cap.2018.0110

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN： 1044-5463            Impact factor:   2.576


× No keyword cloud information.
  4 in total

Review 1.  Efficacy and tolerability of antidepressants in pediatric anxiety disorders: a systematic review and meta-analysis.

Authors:  Jeffrey R Strawn; Jeffrey A Welge; Anna M Wehry; Brooks Keeshin; Moira A Rynn
Journal:  Depress Anxiety       Date:  2014-11-28       Impact factor: 6.505

2.  Weight gain and associated factors in patients using newer antidepressant drugs.

Authors:  Faruk Uguz; Mine Sahingoz; Buket Gungor; Fadime Aksoy; Rustem Askin
Journal:  Gen Hosp Psychiatry       Date:  2014-10-31       Impact factor: 3.238

3.  Efficacy and Safety of Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, and Placebo for Common Psychiatric Disorders Among Children and Adolescents: A Systematic Review and Meta-analysis.

Authors:  Cosima Locher; Helen Koechlin; Sean R Zion; Christoph Werner; Daniel S Pine; Irving Kirsch; Ronald C Kessler; Joe Kossowsky
Journal:  JAMA Psychiatry       Date:  2017-10-01       Impact factor: 21.596

4.  Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial.

Authors:  Graham J Emslie; Daniel Ventura; Andrew Korotzer; Stavros Tourkodimitris
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2009-07       Impact factor: 8.829
  4 in total
  3 in total

1.  Treatment-Resistant Depression in Adolescents: Clinical Features and Measurement of Treatment Resistance.

Authors:  Jeffrey R Strawn; Scott T Aaronson; Ahmed Z Elmaadawi; G Randolph Schrodt; Richard C Holbert; Sarah Verdoliva; Karen Heart; Mark A Demitrack; Paul E Croarkin
Journal:  J Child Adolesc Psychopharmacol       Date:  2020-04-21       Impact factor: 2.576

2.  Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive Disorders.

Authors:  Stacey L Aldrich; Ethan A Poweleit; Cynthia A Prows; Lisa J Martin; Jeffrey R Strawn; Laura B Ramsey
Journal:  Front Pharmacol       Date:  2019-02-19       Impact factor: 5.810

3.  Pharmacogenetically Guided Escitalopram Treatment for Pediatric Anxiety Disorders: Protocol for a Double-Blind Randomized Trial.

Authors:  Jeffrey R Strawn; Ethan A Poweleit; Jeffrey A Mills; Heidi K Schroeder; Zoe A Neptune; Ashley M Specht; Jenni E Farrow; Xue Zhang; Lisa J Martin; Laura B Ramsey
Journal:  J Pers Med       Date:  2021-11-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.